What You Ought to Know:
– LucyRx, a next-generation pharmacy profit supervisor (PBM), introduced it has acquired CerpassRx, a number one PBM identified for its custom-made pharmacy options and medical applications.
– The acquisition, which closed on July 15, 2025, positions the newly mixed firm to serve a broad vary of purchasers, from well being plans and self-funded employers to Taft-Hartley plans.
– The transaction was financed via a mixture of fairness and debt, with fairness traders together with New Mountain Capital and TTV Capital, a technology-focused enterprise capital agency specializing in fintech.
A New Chapter for PBMs: Innovation and Partnership
The mix of LucyRx and CerpassRx marks the creation of a brand new form of PBM powerhouse, designed to fulfill the evolving calls for of the market with a “technology-first, partner-centric method”. The newly merged entity goals to ship superior consumer and member experiences via a mixture of modern expertise, medical excellence, and clear, client-aligned enterprise practices.
CerpassRx, based mostly in Dallas, Texas, has constructed a powerful status for providing versatile, tailor-made pharmacy options and medical applications to its various consumer base. These options span from mail-order and specialty pharmacy to medical applications like opioid administration and formulary optimization. The corporate’s deal with medical worth and consumer partnership aligns seamlessly with LucyRx’s imaginative and prescient.
Following the acquisition, the mixed entity will serve a variety of purchasers, from mid-market well being plans to massive, self-funded employers and Taft-Hartley plans. It’s going to additionally deal with leveraging modern applied sciences to enhance member engagement, drive higher transparency, and simplify pharmacy profit administration for all stakeholders.
